AEterna Zentaris Inc.
1405 du Parc-Technologique Boulevard
Quebec,
QC G1P 4P5
Canada - Map
Phone: 418-652-8525
Fax: 418-652-0881
Web Site: http://www.aeternazentaris.com
| Æterna Zentaris Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for endocrine therapy and oncology. Its lead product candidates in endocrinology are cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist that has completed Phase III trial for benign prostatic hyperplasia (BPH); and AEZS-130, an oral ghrelin antagonist in a Phase III trial as a diagnostic test for Growth Hormone Deficiency. The companys lead products in cancer are perifosine, a PI3K/Akt pathway inhibitor in Phase III for multiple myeloma, and AEZS-108, a Phase II clinical trial product for the treatment of advanced ovarian and endometrial cancers, as well as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma. Its pipeline also include compounds in pre clinical development, such as AEZS-115, an LHRH antagonist for endometriosis and urology; AEZS-120, an anti-cancer vaccine; AEZS-126 Erk and PI3K inhibitors for oncology; and AEZS-127 ErPC for oncology. Æterna Zentaris has partnership agreements with Shionogi and Co.; sanofi-aventis; Nippon Kayaku Co. Ltd.; Spectrum Pharmaceuticals, Inc.; Handok Pharmaceuticals Co., Ltd.; and Keryx Biopharmaceuticals, Inc. The company was founded in 1991 and is headquartered in Quebec, Canada. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Juergen Ernst MBA,
Exec. Chairman and Member of Corp. Governance, Nominating & HR Committee |
$
481.00K | N/A | Prof. Dr. Juergen Engel Ph.D.,
Chief Exec. Officer, Pres, Director, Chairman of Zentaris GmbH and Managing Director of Zentaris GmbH |
N/A
| N/A | Mr. Dennis Turpin C.A.,
Chief Financial Officer and Sr. VP |
N/A
| N/A | Dr. Nicholas J. Pelliccione Ph.D.,
Sr. VP of Regulatory Affairs & Quality Assurance |
$
387.00K | N/A | Mr. Paul Blake MB, FRCP, FCP, FFPM, 61
Chief Medical Officer and Sr. VP |
$
490.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.31% Nasdaq 
0.06 (6.06%) 
Profile
